| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_436c80ac97c18c9be85d896bfe12b8b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b607f0e5cfc30770896a226b4148676c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate |
2015-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22d5478756955989bbda9de5e3f64a48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_972decbb940e15f838b71e848a51b4e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa66482f13c4e1d82d84bdbf508c358
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef74fd991a61a3d4203778df9204e85e |
| publicationDate |
2015-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2935026-A1 |
| titleOfInvention |
Lipidated prolactin-releasing peptides for lowering blood glucose |
| abstract |
Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated analog of prolactin releasing peptide (PrRP)s lowers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity. |
| priorityDate |
2014-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |